New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
09:21 EDTALKS, BIIBAlkermes issued patent for fumarate pro-drug, says Citigroup
Citigroup notes that Alkermes (ALKS) was issued a United States patent for its pro-drug of mono-methyl fumarate, the active ingredient in Biogen's (BIIB) Tecfidera. Citi views the patent as supporting the regulatory potential of ALKS 8700, and notes the drug is a long-term threat to Tecfidera. The firm says Phase 1 data expected by year-end 2014 could be meaningful and keeps a Buy rating on Alkermes with a $60 price target.
News For ALKS;BIIB From The Last 14 Days
Check below for free stories on ALKS;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
09:08 EDTBIIBNektar could see $100M in revenue from Baxter drug, says Roth Capital
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
08:21 EDTBIIBNICE recommends Tecfidera for multiple sclerosis
Dimethyl fumarate is recommended as a possible treatment for people with active relapsing-remitting multiple sclerosis that isn't highly active or rapidly evolving severe relapsing-remitting multiple sclerosis, the U.K.'s National Institute for Health and Care Excellence stated in guidance posted to its website. Reference Link
August 26, 2014
11:21 EDTBIIBBiogen added to short term buy list at Deutsche Bank
07:05 EDTALKSAlkermes initiates Phase 1 clinical study of ALKS 7106 for treatment of pain
Subscribe for More Information
August 25, 2014
07:01 EDTALKSAlkermes submits NDA to FDA for aripiprazole lauroxil
Subscribe for More Information
August 22, 2014
12:39 EDTBIIBThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 18, 2014
11:41 EDTALKSCubist rises after report sparks takeover interest speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use